Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas

Nat Cancer. 2021 Jul;2(7):723-740. doi: 10.1038/s43018-021-00201-z. Epub 2021 May 24.

Abstract

The dynamics and phenotypes of intratumoral myeloid cells during tumor progression are poorly understood. Here we define myeloid cellular states in gliomas by longitudinal single-cell profiling and demonstrate their strict control by the tumor genotype: in isocitrate dehydrogenase (IDH)-mutant tumors, differentiation of infiltrating myeloid cells is blocked, resulting in an immature phenotype. In late-stage gliomas, monocyte-derived macrophages drive tolerogenic alignment of the microenvironment, thus preventing T cell response. We define the IDH-dependent tumor education of infiltrating macrophages to be causally related to a complex re-orchestration of tryptophan metabolism, resulting in activation of the aryl hydrocarbon receptor. We further show that the altered metabolism of IDH-mutant gliomas maintains this axis in bystander cells and that pharmacological inhibition of tryptophan metabolism can reverse immunosuppression. In conclusion, we provide evidence of a glioma genotype-dependent intratumoral network of resident and recruited myeloid cells and identify tryptophan metabolism as a target for immunotherapy of IDH-mutant tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms* / genetics
  • Glioma* / genetics
  • Humans
  • Immunotherapy
  • Isocitrate Dehydrogenase / genetics
  • Tryptophan / therapeutic use
  • Tumor Microenvironment / genetics

Substances

  • Tryptophan
  • Isocitrate Dehydrogenase